The objective is to assess the safety of a monovalent vaccine of a new 6:2 influenza virus reassortant in healthy adults prior to the release of the trivalent vaccine (FluMist®) containing it.
To assess the safety of a vaccine in healthy adults prior to the release of the vaccine (FluMist®) containing it.